These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16876126)

  • 1. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.
    Materna V; Stege A; Surowiak P; Priebsch A; Lage H
    Biochem Biophys Res Commun; 2006 Sep; 348(1):153-7. PubMed ID: 16876126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
    Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
    Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin.
    Xie SM; Fang WY; Liu Z; Wang SX; Li X; Liu TF; Xie WB; Yao KT
    J Transl Med; 2008 Oct; 6():55. PubMed ID: 18834541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
    Priebsch A; Rompe F; Tönnies H; Kowalski P; Surowiak P; Stege A; Materna V; Lage H
    Oligonucleotides; 2006; 16(3):263-74. PubMed ID: 16978089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC transporter cMOAT/MRP2/ABCC2.
    Materna V; Holm PS; Dietel M; Lage H
    Cancer Gene Ther; 2001 Mar; 8(3):176-84. PubMed ID: 11332988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y; Zhou H; Yang S; Su D
    Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.
    Liedert B; Materna V; Schadendorf D; Thomale J; Lage H
    J Invest Dermatol; 2003 Jul; 121(1):172-6. PubMed ID: 12839578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs.
    Folmer Y; Schneider M; Blum HE; Hafkemeyer P
    Cancer Gene Ther; 2007 Nov; 14(11):875-84. PubMed ID: 17704753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.
    Guminski AD; Balleine RL; Chiew YE; Webster LR; Tapner M; Farrell GC; Harnett PR; Defazio A
    Gynecol Oncol; 2006 Feb; 100(2):239-46. PubMed ID: 16213010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ISG15 suppresses translation of ABCC2 via ISGylation of hnRNPA2B1 and enhances drug sensitivity in cisplatin resistant ovarian cancer cells.
    Wang JM; Liu BQ; Zhang Q; Hao L; Li C; Yan J; Zhao FY; Qiao HY; Jiang JY; Wang HQ
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118647. PubMed ID: 31926942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
    Materna V; Liedert B; Thomale J; Lage H
    Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT; Ong CK; Tay SK; Huynh H
    Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene.
    Ma JJ; Chen BL; Xin XY
    Arch Gynecol Obstet; 2009 Feb; 279(2):149-57. PubMed ID: 18584188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
    Materna V; Pleger J; Hoffmann U; Lage H
    Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
    Du P; Zhang X; Liu H; Chen L
    DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
    Duan Z; Brakora KA; Seiden MV
    Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells.
    Valinezhad Sani F; Palizban A; Mosaffa F; Jamialahmadi K
    Eur J Pharmacol; 2020 Feb; 868():172883. PubMed ID: 31866406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA.
    Wu Z; Li X; Zeng Y; Zhuang X; Shen H; Zhu H; Liu H; Xiao H
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):177-84. PubMed ID: 21073659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.